Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v24-FR | Version v8-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2022-02-28 | 2021-11-16 |
| Drug Identification Number | 02141019 | 02141019 |
| Brand name | CALCIUM GLUCONATE INJECTION, USP 10% | CALCIUM GLUCONATE INJECTION, USP 10% |
| Common or Proper name | Calcium Gluconate Injection, USP 10% 100 mg/mL SD Vial (Plastic) 100 mL | Calcium Gluconate Injection, USP 10% 100 mg/mL SD Vial (Plastic) 100 mL |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | CALCIUM GLUCONATE | CALCIUM GLUCONATE |
| Strength(s) | 100MG | 100MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 100 mL | 100 mL |
| ATC code | B05BB | B05BB |
| ATC description | I.V. SOLUTIONS | I.V. SOLUTIONS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2021-11-01 | 2021-11-01 |
| Actual start date | 2021-02-01 | 2021-11-01 |
| Estimated end date | 2022-03-07 | 2021-12-31 |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Effective Mar. 7, 2022, 100mL will be used to cover 100% of 100mL demand plus 100% of 50mL demand on a mL per mL basis for contract customers. Please see customer communication. | Allocation strategy implemented to stretch inventory and ensure equitable distribution. Please see customer communication. |
| Health Canada comments |